ASP Isotopes Inc. 8-K Filings

ASP Isotopes Inc. (ASPI) announced it is hosting its inaugural Capital Markets Day in London, providing an operational and strategic update across nuclear medicine, electronics, helium and LNG, and nuclear fuels. Management highlights that the past 12 months marked a shift from development into early commercialization in several businesses.

The company plans to discuss target milestones for the next 12 months, including expected revenue growth from initial liquid helium production as Phase 1 of the Virginia Gas Project is completed, continued growth of its radiopharmacies, and first commercial shipments from its stable isotope division. These developments are presented as steps toward a stated EBITDA target of more than $300 million in 2031.

ASP Isotopes also continues to pursue separate public listings for Quantum Leap Energy and Noble Africa, and references proposed transactions involving ENDRA Life Sciences, Renergen and Noble Africa that will be detailed in a future Form S-4 and proxy statement. The company emphasizes extensive forward-looking and projections-related cautionary language and clarifies that EBITDA is a non-GAAP financial measure.

ASP Isotopes Inc. (ASPI) reported that its wholly owned subsidiary Renergen Limited entered into a Second Amendment and Restatement Agreement with The Standard Bank of South Africa, replacing a prior secured term loan facility. The amended facility provides a secured ZAR230,532,658.90 term loan (approximately USD14.2 million) that now includes previously accrued, unpaid and capitalized interest from the earlier agreement.

The loan bears interest at the Compounded Reference Rate plus 1.46%, for an effective rate of 8.31%, and matures on August 14, 2027. Renergen must maintain a Collateral Account with the lender with a balance at least equal to the full commitment, over which the lender has exclusive control and from which it may debit interest on each payment date. The agreement imposes negative covenants and broad cross-default provisions tied to financial indebtedness of Renergen, Tetra4, NTIGT and ASP Isotopes. In a related Put Option Agreement, ASP Isotopes granted the lender an irrevocable right, upon a continuing Event of Default, to require ASP Isotopes or its nominee to purchase 1,546,268 pledged ASP Isotopes shares at 100% of the five-day JSE volume-weighted average price, with proceeds applied to reduce or discharge the loan.

ASP Isotopes Inc. (ASPI) reports that Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project in South Africa, has entered the commissioning phase of ASP’s liquid helium plant. First commercial helium shipments to customers are expected during September, with production ramping to nameplate capacity in the second half of 2026.

Phase 1 of the project is expected to produce approximately 2,500 GJ/day of LNG and 70 Mcf/day of liquid helium, supporting projected annualized revenues of over $27 million once fully ramped, based on stated price assumptions. ASP currently has take-or-pay contracts covering about 75% of Phase 1 LNG and 15% of Phase 1 helium volumes.

ASP plans a much larger Phase 2, targeted to be roughly 13 times the size of Phase 1, with construction expected to start in the second half of 2026 and take about 44 months. The company intends to pursue up to $750 million in senior debt funding from the U.S. International Development Finance Corporation and Standard Bank of South Africa, subject to negotiation and definitive agreements. The disclosure also describes a planned reverse merger involving Noble Africa and ENDRA Life Sciences and related SEC filings.

ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC, is evaluating metal conversion opportunities in Namibia. The subsidiary has begun a public environmental and social impact assessment and consultation process for a proposed pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area. The potential facility would be used to develop, test, and demonstrate hydrofluorination and fluorination processes for metals. The evaluation is at an early stage, with no final investment decision made, and any future development would be subject to technical, commercial, environmental, and regulatory review and approvals.

Quantum Leap Energy is described as a development-stage nuclear fuels company focused on uranium conversion, enrichment technologies and isotopic separation for advanced reactors and fusion systems, while ASP Isotopes develops isotope enrichment technologies for nuclear medicine, semiconductors, and nuclear energy.

ASP Isotopes describes that Tetra4 Proprietary Limited, a subsidiary of its subsidiary Renergen Limited, has signed a new five-year, take-or-pay contract to supply liquified natural gas to a South African food processor at a price per unit of greater than $16/GJ of LNG on an all-in plant-gate basis. The agreement represents about 10% of the Virginia Gas Project's Phase 1 nameplate capacity and, together with earlier contracts, supports roughly 75% of anticipated Phase 1 LNG volumes.

Phase 1 is expected to produce approximately 2,500 GJ/day of LNG and about 70 Mcf/day of liquid helium, with commercial production targeted to begin in the third quarter of 2026. ASP Isotopes states that, assuming LNG prices of $15–18 per GJ and an average helium price of $600/Mcf, Renergen should be capable of generating revenues of over $27 million on an annualized basis following completion of Phase 1, with revenue recognition expected to begin in the second half of 2026. The company also outlines a planned reverse merger of its Noble Africa subsidiary with ENDRA Life Sciences and related SEC registration and proxy processes.

ASP Isotopes Inc. disclosed that it will host investor meetings at Citi's 2026 Natural Resources Conference on August 13, 2026, in Las Vegas, Nevada. The latest investor presentation is available under the Investors tab on the company’s website.

The press release also describes ASP Isotopes’ isotope enrichment technologies and facilities in Pretoria, South Africa, and outlines proposed merger-related transactions involving ENDRA Life Sciences, Renergen and Noble Africa, for which ENDRA plans to file a Form S-4 registration statement with a proxy statement/prospectus. It emphasizes extensive forward-looking statements and risk factors, including funding needs, regulatory approvals, project execution, and the possibility that the proposed transactions may not be completed.

ASP Isotopes updates shareholders on multi‑segment growth plans ahead of releasing Q2 2026 results. Management reports that PET Labs achieved over 50% organic revenue growth in 1H 2026 and forecasts FY 2026 revenue of approximately $14 million, compared with $6 million in 2025, as demand for radiopharmaceuticals rises.

Through Renergen, the company targets helium and LNG revenues of roughly $27 million annually after Phase 1, and over $360 million at Phase 2 nameplate capacity, at stated price assumptions. Phase 2 is expected to be funded in part by about $750 million of senior debt, and ASP Isotopes plans to list Renergen’s holding vehicle Noble Africa on Nasdaq, where it expects to retain roughly 89% ownership if the transactions close.

The update highlights delays but continued technical progress in Silicon‑28 and other stable isotope facilities, a long‑term EBITDA target above $300 million by 2031 from non‑nuclear‑fuel businesses, and strategic plans for Quantum Leap Energy and Alpa Theranostics, including a potential future distribution of QLE equity to ASP Isotopes shareholders, subject to multiple conditions.

ASP Isotopes Inc., an advanced materials company developing isotope enrichment technologies, announced that Chief Commercial Officer Viktor Petkov will present at Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026, at 8:00 a.m. ET. A live audio webcast and subsequent replay will be available in the Investors section of the company’s website.

The press release also describes proposed merger and related transactions involving ENDRA Life Sciences Inc., ASP Isotopes and its subsidiaries Renergen and Noble Africa, for which ENDRA plans to file a Form S-4 registration statement containing a proxy statement and prospectus. It includes extensive "forward-looking" statements language, highlighting risks around project execution, regulatory approvals, financing, commercialization of isotope technologies, completion of the Proposed Transactions (including approval by ENDRA stockholders), and other factors discussed in ASP Isotopes’ 2025 Annual Report and subsequent SEC reports.

ASP Isotopes Inc. plans to hold a Capital Markets Day in London on September 8, 2026, beginning at 10:00 a.m. ET (3:00 p.m. BST). Leadership intends to provide a comprehensive update on strategic direction and commercial momentum, including nuclear medicine, electronic gases, nuclear fuels, and the long-term market opportunity in each area.

The event will run from 10:00 a.m. to 12:30 p.m. ET with a formal Q&A; in-person attendance is invitation-only, but the public can join via live webcast, with materials and a replay available on the company’s investor relations website. The disclosure is furnished under Regulation FD, not filed.

The communication also describes a proposed merger and related transactions involving ENDRA Life Sciences, Renergen, and Noble Africa, stating that ENDRA intends to file a Form S-4 with a proxy statement/prospectus and urging ENDRA stockholders to review those materials when available. Extensive cautionary language outlines that forward-looking statements, including expectations about the proposed transactions and ASP Isotopes’ projects and regulatory approvals, are subject to numerous risks and uncertainties.

ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy LLC (QLE), has entered into a research agreement with the Texas A&M Engineering Experiment Station (TEES) to advance and de‑risk the commercial production of high-purity uranium hexafluoride (UF6), a key feedstock in the nuclear fuel enrichment supply chain.

The collaboration will generate fundamental physicochemical data on converting yellowcake uranium (U3O8) into UF6, supporting efforts to improve production technology, reduce costs, and enhance scalability for domestic uranium conversion. QLE is a development-stage nuclear fuels company focused on uranium conversion, U‑235 enrichment (including HALEU, LEU+ and LEU), lithium isotope separation, and radioactive waste treatment, using proprietary Aerodynamic Separation Process and Quantum Enrichment technologies. ASP Isotopes develops isotope enrichment platforms and operates enrichment facilities in Pretoria, South Africa. The announcement includes extensive cautionary language regarding forward-looking statements and related risks.

ASP Isotopes Inc. plans to exchange a portion of the convertible promissory notes of its wholly owned subsidiary, Quantum Leap Energy (QLE), for common equity in ASP Isotopes. Holders of approximately $109.2 million in aggregate principal amount of QLE convertible notes, plus accrued interest, have agreed to receive an aggregate of approximately 23.2 million shares of ASP Isotopes common stock, representing approximately 17.8% of ASP Isotopes’ common stock outstanding.

At closing, QLE’s outstanding convertible notes are expected to be reduced by approximately 50%, from $219.8 million to $110.7 million in aggregate principal amount, simplifying QLE’s capital structure as it pursues a separate public listing on a U.S. national securities exchange. The exchange transactions are also expected to support ASP Isotopes’ position for a potential future distribution of its QLE common equity to ASP Isotopes stockholders, and are expected to close on July 16, 2026, subject to customary conditions.

ENDRA Life Sciences Inc. has adopted an Amended and Restated Certificate of Incorporation for Noble Africa Inc., setting a new capital structure and governance framework under Delaware law. The charter authorizes 1,250,000,000 shares split into dual‑class common stock and preferred stock.

The new structure creates Class A Common Stock with one vote per share and Class B Common Stock with ten votes per share, with automatic and voluntary conversion mechanisms into Class A. It also empowers the board to create multiple series of preferred stock, establishes a classified board, defines stockholder voting and consent rights, and includes liability protections, indemnification, corporate opportunity waivers, business combination restrictions, and Delaware‑focused forum selection clauses.

ASP Isotopes Inc. outlined a proposed merger in which its wholly owned subsidiary Noble Africa LLC would combine with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity. The combined company plans to be named Noble Africa Inc. and apply to list on Nasdaq under the ticker “NOBA.”

Alongside the merger, Noble Africa has secured commitments for a private placement expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes as lead investor and about $30 million from other investors, with $750,000 from certain ASP Isotopes directors and management. At closing, ASP Isotopes is expected to own about 89% of the combined company, pre-closing ENDRA stockholders about 3%, and other private placement investors about 7%, with closing targeted for the third or fourth quarter of 2026, subject to regulatory and stockholder approvals and other customary conditions.

ASP Isotopes Inc. announced that Tetra4, the Renergen subsidiary developing the Virginia Gas Project in South Africa, has signed its first five-year take-or-pay contract to sell liquid helium to an Asian industrial gases company at an initial base price above $600/MCF. The agreement covers about 15% of expected Phase 1 helium capacity and helps underpin multi-year cash flow ahead of targeted commercial production in the third quarter of 2026. Phase 1 is planned to produce roughly 70 MCF/day of liquid helium and 2,500 GJ/day of LNG, with Phase 2 targeted at about 900 MCF/day of helium and 34,000 GJ/day of LNG, supported by conditional approval for up to $750 million in senior debt financing.

ASP Isotopes Inc. reported operational progress at its Silicon-28 enrichment facility in Pretoria, South Africa. The company has successfully restarted the first 18 stages of the plant after nine months of engineering enhancements to non-core components such as valves, compressors, and piping, and these stages have operated for over three weeks at target enrichment levels.

The company has signed three commercial contracts to supply enriched Silicon-28 to U.S.-based customers and expects initial commercial shipments to begin in Q3 2026. Earlier, it shipped first samples in August 2025, with independent analysis confirming enrichment performance. The release highlights Silicon-28’s potential importance for quantum computing and next-generation semiconductors.

ASP Isotopes Inc. furnished an update under Regulation FD by releasing its latest investor presentation on May 20, 2026. The presentation is available on the company’s website home page.

The company states the presentation is not deemed “filed” under the Exchange Act or Securities Act and will not be incorporated by reference into other SEC filings. It includes safe harbor language indicating that some content consists of forward-looking statements subject to risks described in ASP Isotopes’ most recent Form 10-K and other SEC reports.

ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy, announced a non-binding Memorandum of Understanding with a European nuclear technology company to explore a long-term collaboration for advanced nuclear fuel supply.

The MOU covers potential supply of high assay low enriched uranium (HALEU) with uranium-235 content greater than 10%. The parties plan technical and economic assessments, with a framework where the partner could provide uranium feedstock to Quantum Leap Energy’s planned conversion and enrichment facilities, and Quantum Leap Energy could enrich and potentially deconvert it for delivery.

The MOU runs through December 31, 2030, and contemplates non-binding estimates of HALEU quantities, with potential deliveries beginning in 2028 and volumes scaling up through 2036, aligned with the partner’s reactor development timeline and fuel needs.

ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has appointed Dr. Peter S. Fiske to QLE’s Strategic Advisory Board. QLE focuses on innovative technologies across the nuclear fuel cycle, including uranium enrichment and lithium isotope separation, using proprietary Aerodynamic Separation Process and Quantum Enrichment technologies.

Dr. Fiske previously led the U.S. Department of Energy’s five-year, $110 million National Alliance for Water Innovation hub and has extensive experience in technology commercialization, government partnerships, and advanced materials. The press release also reiterates QLE and ASP Isotopes’ use of forward-looking statements subject to significant technical, regulatory, and funding risks.

ASP Isotopes Inc. provided a broad business and financial update, pairing strong balance sheet growth with long‑term profitability goals. The company reported cash, cash equivalents and marketable securities of $333 million as of December 31, 2025, after raising over $345 million in 2025 through common stock and convertible notes. Product revenue for 2025 was $5.7 million, up 46% from $3.9 million in 2024, while net loss attributable to shareholders widened to $175.1 million from $32.3 million.

Management outlined a long‑term EBITDA target of more than $300 million in 2031 and expects first commercial isotope shipments in 2026 across Silicon‑28, Carbon‑14 and Ytterbium‑176. The Virginia Gas Project’s Phase 1 drilling finished roughly four months early, with nameplate capacity of 2,500 GJ per day of LNG and 58 MCF per day of liquid helium expected in the third quarter of 2026.

ASP Isotopes Inc. announced that Executive Chairman and CEO Paul Mann will host a business update conference call and webcast on April 13, 2026, at 8:00 AM ET. Investors and the public can join via toll and toll-free numbers or a live webcast, with a replay available on the company’s website.

The company develops proprietary isotope enrichment technologies, including its Aerodynamic Separation Process and Quantum Enrichment, to supply critical materials for nuclear medicine, advanced semiconductors, and nuclear energy. The announcement also highlights that management may discuss forward-looking statements during the call, which are subject to significant risks and uncertainties.

Renergen, whose Virginia Gas Project underpins ASPI’s interest, outlines extensive risks around expanding Phase 2. The project demands large, uncertain capital outlays, complex permitting and reliance on conditional debt facilities of up to $500 million from DFC and $250 million from Standard Bank that carry stringent conditions.

The company faces exposure to inflation, higher interest rates, supply chain constraints, power and water shortages, and South Africa–specific socio‑economic and political risks. Operational challenges span drilling complexity, pipeline construction, contractor dependence, cybersecurity, data‑privacy compliance, and concentrated single‑site exposure. High leverage, covenant limits and potential impairment if projects underperform could pressure liquidity and future results.

ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy, has begun a strategic collaboration with the University of Bristol to design a state-of-the-art lithium laser enrichment research facility in the UK. Bristol will lead a roughly four-month initial phase focused on feasibility and detailed technical design.

The work covers concept design, engineering specifications and safety reviews, progressing to completion of RIBA Stage 4 technical design. If the feasibility assessment is positive, the parties intend to build the facility at a suitable off-campus University of Bristol site for research commissioned and funded by Quantum Leap Energy, targeting advanced lithium-6 and lithium-7 enrichment for next-generation fission and fusion nuclear fuels.

ASP Isotopes reports a major milestone at its Virginia Gas Project, completing all wells required for Phase 1 of the Renergen Helium Project about four months ahead of schedule. Drilling results from the Phase 1C campaign indicate reservoir gas flow rates that meet or exceed earlier type-curve estimates, easing historic constraints on plant utilisation and helium production.

The Phase 1 drilling program has now achieved the required cumulative nameplate flow rate, meaning remaining work to reach full output is largely engineering-focused. Some new wells are delivering gas flow rates up to 16 times those of certain earlier wells, and the company plans to tie these into the processing plant over the coming months. After planned completion of Phase 1 during 2026, ASP Isotopes expects production of 2,500 GJ per day of LNG and 58 MCF per day of liquid helium, rising after Phase 2 to 34,000 GJ per day of LNG and 895 MCF per day of liquid helium.

The update comes as global helium supply tightens due to the closure of the Strait of Hormuz and reported damage at Ras Laffan in Qatar, which supplied about 2.3 billion scf of helium in 2025. The company highlights South Africa’s geopolitical neutrality and backing from the U.S. International Development Finance Corporation as advantages for positioning the Virginia Gas Project as a significant new source of liquid helium.

ASP Isotopes Inc. announced that CEO Paul Mann will participate in a fireside chat at Canaccord Genuity’s 2nd Annual CG Virtual Sustainability Summit on March 12, 2026, at 3:20 p.m. ET. The event will be held virtually and focuses on sustainability-related topics.

A live audio webcast of the presentation will be available in the Investors section of the company’s website, with a replay accessible within 48 hours. The company highlights its work on proprietary isotope enrichment technologies for applications in nuclear medicine, advanced semiconductors, and nuclear energy, and includes extensive cautionary language about forward-looking statements and related risks.

ASP Isotopes, through its subsidiary Quantum Leap Energy (QLE), has signed a non-binding memorandum of understanding with a large publicly traded U.S. energy company that operates nuclear power stations. The partner will evaluate options to support QLE’s plans to build advanced nuclear fuel cycle facilities in the United States.

The planned facilities would produce high assay low enriched uranium (HALEU) and low enriched uranium plus (LEU+), and provide uranium conversion and deconversion services. QLE aims to supply HALEU for advanced and small modular reactors and offer LEU+ to the existing reactor fleet to lengthen refueling intervals, cut costs, and increase power output.

QLE positions this initiative as a step toward strengthening the domestic nuclear fuel supply chain amid a federal ban on Russian uranium imports starting in 2028 and growing demand from next-generation reactor developers.

ASP Isotopes’ subsidiary Quantum Leap Energy appointed Nate Salpeter, Ph.D., as Chief Technology Officer. He is a recognized expert in fluid dynamics and energy technology optimization with more than 15 years of experience building computational, experimental, and engineering programs in advanced nuclear and thermal systems.

Dr. Salpeter previously held senior technical roles at TerraPower and Kairos Power, where he helped establish core fluid dynamics and modeling capabilities for next‑generation reactor projects. At Quantum Leap Energy, he will focus on optimizing in‑licensed and proprietary technologies, implementing rapid learning cycles, and leading methodical de‑risking to support commercialization of the company’s nuclear fuel and clean energy technologies.

The announcement highlights Quantum Leap Energy’s strategy as a development‑stage nuclear fuels company using Aerodynamic Separation Process and Quantum Enrichment technologies to address gaps in the nuclear fuel cycle for advanced reactors, small modular reactors, and fusion systems, supported by partnerships with leading industry and research organizations.

ASP Isotopes’ subsidiary Quantum Leap Energy has deepened its collaboration with the South African Nuclear Energy Corporation (Necsa) by signing a Pre-Implementation Services Contract for a planned High Assay Low Enriched Uranium (HALEU) enrichment facility at Necsa’s Pelindaba site.

Under the agreement, Necsa will provide facilities, infrastructure, utilities and services to support the siting, design, construction, commissioning and operation of the enrichment facility. A joint committee with representatives from both parties will oversee implementation, aiming to bring QLE’s HALEU production capabilities to market readiness.

The partnership combines QLE’s proprietary Aerodynamic Separation Process and Quantum Enrichment technologies with Necsa’s established nuclear infrastructure and global networks. It targets growing demand for HALEU, a key fuel for small modular and other advanced reactors, as advanced nuclear projects scale to serve data centers and industrial electrification.

ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy (QLE), has created a Strategic Advisory Board to support its plans in the nuclear fuel sector and appointed two initial members, nuclear engineering academic leader Mary Lou Dunzik-Gougar and advanced materials executive Kevin Kramer.

The board is expected to guide QLE as it develops proprietary technologies to address inefficiencies, environmental concerns, and supply chain vulnerabilities across the nuclear fuel cycle, including front-end enrichment activities and back-end waste treatment technologies for advanced reactors, fusion systems, and the existing nuclear fleet.

ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy (QLE), plans to establish QLE’s new global corporate headquarters in Austin, Texas. The move is intended to strengthen its Texas presence and position the development-stage nuclear fuels company closer to its U.S. customer base.

QLE also plans a significant operational presence in Texas, working with Fermi America under an existing memorandum of understanding to pursue a joint venture for a high-assay low-enriched uranium enrichment research and commercial production facility linked to Fermi America’s hypergrid campus in Amarillo. This would be developed alongside ASP Isotopes’ planned commercial facility for stable isotopes and advanced nuclear materials.

The announcement highlights Texas’ supportive regulatory and business environment for nuclear power and notes U.S. Department of Energy estimates that domestic demand for HALEU could reach 50 metric tons per year by 2035 and 500 metric tons per year by 2050, underscoring the potential market for advanced nuclear fuels.

ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock at an original purchase price of $2.2952 per share. The preferred stock is convertible into Opeongo common stock and carries anti-dilution protections, voting rights, and the ability for Series Seed-1 holders to elect a dedicated director while enough shares remain outstanding.

ASP Isotopes and other investors also received veto rights over certain major Opeongo corporate actions and contractual protections through investors’ rights, right of first refusal and co-sale, and voting agreements. Within thirty days after January 26, 2026, ASP Isotopes and Opeongo are obligated to negotiate a draft supply agreement giving ASP Isotopes a right of first offer for medical isotope supply tied to Opeongo’s future pharmaceutical products.

ASP Isotopes Inc. filed a current report to share that it issued a press release providing a production update on the Helium Project of Renergen Limited. The press release, dated January 29, 2026, is attached as Exhibit 99.1 and is incorporated by reference into the report.

The information is furnished under Regulation FD, meaning it is intended to ensure broad, non-selective disclosure. The company also notes that the press release contains forward-looking statements covered by the Private Securities Litigation Reform Act safe harbor provisions.

ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026. Renergen’s Chief Executive Officer, Stefano Marani, has been appointed President, Electronics and Space of ASP Isotopes, and Renergen’s Chief Operating Officer, Nick Mitchell, has been appointed Co-Chief Operating Officer of ASP Isotopes.

The company expects to enter into employment agreements providing Mr. Marani a base salary of $550,000 per year and Mr. Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock. Each executive has been approved for a grant of 700,000 shares of common stock, vesting in eight equal installments over four years, with 87,500 shares vesting on each six‑month anniversary of employment, subject to continued service.

The stock awards are being made under ASP Isotopes’ inducement equity incentive plans in line with Nasdaq Listing Rule 5635(c)(4), and both executives will also be eligible for annual equity awards under the company’s 2022 Equity Incentive Plan. Due to prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement, the company notes that Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest in such dealings for related‑party disclosure purposes.

ASP Isotopes Inc. completed its previously announced acquisition of Renergen Limited on January 6, 2026. ASP Isotopes acquired all issued Renergen ordinary shares via a South African court-approved scheme of arrangement, paying with shares of its own common stock.

Renergen shareholders received 0.09196 ASP Isotopes common shares for each Renergen ordinary share, resulting in the issuance of 14,270,000 new ASP Isotopes shares. Following the deal, Renergen became a direct, wholly owned subsidiary, and its shares will be delisted from the Johannesburg Stock Exchange, the Australian Securities Exchange and A2X, while ASP Isotopes stock remains listed on Nasdaq and the JSE.

Renergen executives are joining ASP Isotopes’ leadership, with CEO Stefano Marani becoming President, Electronics and Space, and COO Nick Mitchell becoming Co-Chief Operating Officer. The consideration shares were issued in an unregistered transaction relying on Rule 802, and ASP Isotopes plans to file required acquired-business financial statements and pro forma information in a later amendment.

ASP Isotopes Inc. reports that the South African Takeover Regulation Panel has issued a compliance certificate for its planned acquisition of Renergen Limited. This clears a key regulatory step so the South African law scheme of arrangement can proceed to implementation. Under the Scheme, Renergen shareholders are to receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.

The company outlines a detailed timetable through early January 2026, including suspensions of Renergen trading on the JSE and ASX, the listing of ASP Isotopes consideration shares, the Scheme implementation date, settlement of new shares, and payment of cash for fractional entitlements. The disclosure also highlights cross-border settlement mechanics and reiterates risks that the Scheme may not be implemented as anticipated or that expected benefits from the Renergen acquisition may not be realized.

ASP Isotopes Inc. reported that, on December 17, 2025, it obtained all required regulatory approvals and clearances for its proposed offer to acquire all of the issued ordinary shares of Renergen Limited.

The transaction is structured as a scheme of arrangement under South African law, under which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date. The company also issued a press release describing the receipt of these approvals.

ASP Isotopes Inc. reported a leadership update. Founder and Executive Chairman Paul Mann will resume his role as the company’s Chief Executive Officer, while continuing as Executive Chairman, after a temporary leave of absence. His return to the dual role is effective January 19, 2026. The company disclosed this change in connection with a press release dated December 2, 2025.

ASP Isotopes Inc. filed a Form 8-K to furnish an investor presentation connected to its previously announced quarterly business update conference. On November 21, 2025, the company released a "Third Quarter Update Call" presentation, dated as of November 2025, which is attached as Exhibit 99.1. The information in the presentation is provided as of November 2025, and the company states it does not assume any obligation to update it. The material is furnished under Regulation FD and is expressly not deemed "filed" for purposes of certain liability provisions of the federal securities laws.

ASP Isotopes Inc. reported that it will host a quarterly business update conference call and webcast on November 21, 2025 at 8:30 a.m. Eastern Time. The company disclosed this plan in a current report and attached the related press release as an exhibit, noting that the call will provide a regular update on its business activities. The press release is furnished for information purposes and is not treated as filed under securities law.

ASP Isotopes Inc. reports that its wholly owned subsidiary Quantum Leap Energy LLC plans to issue approximately $64.3 million of unsecured convertible promissory notes to accredited and non-U.S. investors. The QLE 2025 Notes bear 8.0% annual interest, with principal and interest due on demand by majority noteholders on or after the five-year anniversary of the initial closing. QLE expects to use the net proceeds to build and develop laser enrichment production facilities and for general corporate purposes.

Existing 2024 convertible notes will automatically convert into QLE 2025 Notes at the initial closing, without additional proceeds to QLE or ASPI. The notes convert into equity upon a stock exchange listing, a qualifying equity financing of at least $20 million, certain corporate transactions, or at maturity, generally at a 20% discount or a valuation-based price formula. Holders who do not convert in a qualifying corporate transaction are entitled to unpaid interest plus 1.5× principal. A registration rights agreement will grant demand and piggyback registration rights, including the ability to demand an initial public offering if QLE has not gone public within five years.

ASP Isotopes Inc. (ASPI) announced that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has confidentially submitted a draft registration statement on Form S-1 to the SEC for a proposed initial public offering of QLE’s Class A common stock.

The disclosure was furnished under Item 7.01 (Regulation FD) and, along with the accompanying press release, was issued pursuant to Rule 135. The notice states it does not constitute an offer to sell or a solicitation to buy any securities and will be subject to the registration requirements of the Securities Act.

ASP Isotopes (ASPI) furnished an update on its subsidiary financing. Quantum Leap Energy (QLE), a wholly owned subsidiary, issued an investor presentation and commenced a private placement of QLE convertible promissory notes. QLE entered a definitive purchase agreement for an initial closing of $64.3 million of QLE Notes, led by American Ventures LLC, with ASP Isotopes also making a significant investment. QLE may issue additional notes in subsequent closings to non‑U.S. persons in transactions outside the United States in reliance on Regulation S.

The investor presentation (Exhibit 99.1) and a press release (Exhibit 99.2) are included as exhibits. The information was furnished under Regulation FD and is not deemed filed under the Exchange Act.

ASP Isotopes Inc. (ASPI) reported a corporate update. The company announced that its U.K. subsidiary, Quantum Leap Energy Ltd., has commenced early engagement for regulatory pathways with U.K. nuclear regulators.

The announcement was made via a press release, which is furnished as Exhibit 99.1 and incorporated by reference in this report, other than the fourth and eighth paragraphs of that press release.

ASP Isotopes (ASPI) reported that its subsidiary, Quantum Leap Energy LLC, has completed the purchase of certain assets from One 30 Seven Inc. to advance solutions for processing nuclear waste. The company furnished this update under Item 8.01 and attached a press release as Exhibit 99.1, noting that the ninth paragraph of the release is not incorporated by reference.

ASP Isotopes Inc. entered into an underwriting agreement to sell 17,167,380 shares of common stock at $11.65 per share. The underwriters have a 30‑day option to purchase up to 2,575,106 additional shares at the same price.

Gross proceeds are expected to be approximately $210.3 million before underwriting discounts, commissions, and offering expenses. The offering is expected to close on October 16, 2025, subject to customary closing conditions. The sale is being made under the company’s effective Form S‑3 registration statement with a related prospectus and prospectus supplement. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are acting as underwriters.

ASP Isotopes Inc. reported business updates via Form 8-K. The company announced a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the United States. A press release with details is furnished as Exhibit 99.1.

ASP Isotopes (ASPI) announced a leadership transition. Effective October 1, 2025, founder Paul Mann became Executive Chairman and began a temporary leave from Chief Executive Officer duties for health reasons. The Board appointed Chief Operating Officer Robert Ainscow as Interim CEO (principal executive officer) in addition to his current role.

Mr. Mann will guide strategy and support senior management alongside the Board, while Mr. Ainscow will manage CEO direct reports and external communications. The company made no new employment arrangements for Robert Ainscow. The filing notes Robert is the brother of Donald Ainscow, EVP, General Counsel and Secretary, whose compensation includes a base salary of $425,000 and an initial grant of 400,000 shares vesting over four years.

ASP Isotopes Inc. reported that it has received a purchase order for enriched Barium-137 from a U.S.-based customer. This order relates to the company’s specialized isotope products and reflects commercial demand from a domestic buyer.

The company communicated this development through a press release dated September 30, 2025, which is included as an exhibit to this report for investors seeking additional operational detail.

ASP Isotopes Inc. filed a Form 8-K to report that it issued a press release on September 29, 2025 announcing changes to the executive management teams of ASP Isotopes Inc. and its subsidiary, Quantum Leap Energy LLC, effective October 1, 2025. The press release describing these leadership changes is included as Exhibit 99.1 and incorporated by reference, except for its third through seventh paragraphs.